Strategic position of the Leeds Institute of Cardiovascular and Metabolic Medicine
80% of people who have diabetes currently die because of the cardiovascular complications caused by their diabetes. The complications are aggressive types of cardiovascular disease which are increasingly a feature of middle age and more difficult to treat than cardiovascular disease in the absence of diabetes. As well as premature death, the complications lead to disabilities, reduced ability to work and reduced quality of life. Although the heart is impacted, the underlying abnormalities most commonly originate in blood vessels which are critical for the health of all organs, so implications span the whole body, ranging from intolerance to physical exercise, lower limb ulceration, accelerated arthritis, impaired auditory and visual acuity, renal failure, sexual dysfunction, and dementia. The scale of this problem is enormous and strongly anticipated to increase in the UK and many other countries worldwide. Current treatment options are limited and largely fail to address the problem. Therefore urgent and long-term scientific progress is required alongside educational, health service and public health efforts.
The institutes mission is to discover new principles for detecting and treating cardio metabolic disease and to educate people so that they too can address the disease problem or support such efforts.
· The University of Leeds and the Leeds Teaching Hospital Trust are home to one of the largest, most vibrant and successful cardio metabolic research, training and treatment centres in the UK.
· The institute is the core structure and home for this activity, reaching out to others at Leeds through MCRC (http://www.cardiovascular.leeds.ac.uk/) and to other institutions through North of England university networks and academic collaborations worldwide.
· There are 200 staff members in the institute organised into departments for discovery and translational science, biomedical imaging science, clinical and population science and specialist science education which support programmes of activity and are supported by cross-cutting academic action groups, professional services and a core team of technicians and technologists. In the past 2 years there have been 2 internal promotions to Professor and 15 new-blood academic appointments (2 Professors, 2 Lecturers and 11 tenure-track University Academic Fellows).
· The institutes research covers many aspects of the cardio metabolic topic and includes research excellence in critical biology and technology: vascular mechanical sensation, vascular insulin sensitivity, blood-clot structure and platelet biology, imaging, and patient data analysis. Publications regularly appear at the highest levels including in Nature, Nature Communications, Annals of Internal Medicine, Angewandte Chemie International Edition, Circulation, JAMA, JACC, Diabetes Care, ELife, Circulation Research, Blood, EMBO J and Diabetes.
· The institute is home to major British Heart Foundation (BHF) research awards which include 2 BHF Chairs, 5 BHF programme grants, a BHF Strategic Imaging Award, a BHF 4-Year PhD Programme in Cardiovascular Disease and Diabetes, and 4 BHF Intermediate Research Fellowships (3 Clinical, 1 Basic Science). The institutes overall research portfolio shows a broad funding base spanning the Wellcome Trust (2 Investigator Awards, 1 Fellowship), MRC, BBSRC, NIHR, EU, Diabetes UK, Medtronic and a spectrum of other charities and industrial sponsors.
· The centre-piece physical home of the institute is the LIGHT Building, completed in 2005 and comprising 3000 m2 of stylish laboratory and office space. High-end technical capabilities operate as core facilities including preclinical imaging and advanced cellular imaging.
· The adjacent Leeds General Infirmary houses the institutes cardiovascular clinical research facility and outstanding CMR research facilities including the MRC-funded Advanced Imaging Centre. To the other side, in the Worsley Building, is the MRC-funded Data Analytics Centre which is home to institute epidemiology investigators. Across the road there is a state-of-the-art murine facility and the Astbury Centre for Structural and Molecular Biology.
· The institute has major interests in student education, scholarship and cutting edge educational approaches. As well as contributing importantly to the School of Medicines MBChB programme it is home to intercalated programmes in cardiovascular medicine and medical imaging, professionally accredited undergraduate programmes in diagnostic radiography, cardiac physiology and audiology and postgraduate programmes in medical imaging, embryology, health data analytics and professionally accredited programmes in diagnostic imaging. Its International PhD Academy will have its first student intake in 2018.
· To make increasingly important and timely discoveries of new principles for detecting and treating cardio metabolic disease
· To deliver increasingly high quality and impactful education to more people and across a greater spectrum of backgrounds so that more people across the breadth of our society and partner societies can address and better address the disease problem or support such efforts
· To deliver the institutes vision
· To maximise the institutes volume of academic excellence by maximizing its number of: capable and motivated home and international students and the quality of their education, progression and life-long support; timely 3- and 4-star outputs (UK government REF definition); fully economically costed (fEC) and 5-year programmatic grants; Fellows of the Academy of Medical Sciences or equivalent and externally-funded fellows and professors
· To lead and work collectively on a seminal initiative to change thinking and improve treatment options in the cardio metabolic arena
· To coordinate effectively with the School of Medicine, University and Leeds Teaching Hospitals Trust
· To be financially stable
· Invest in activity which aligns to the vision and priorities